A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from birth
- Protection achievable with 2-week gap before premature birth
- Vaccination in third trimester still provides significant infant protection
Compelling evidence from recent research
The efficacy of the pregnancy RSV vaccine has been established through a extensive research programme carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable information of the vaccine’s real-world impact. The study’s results have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research provides healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across different groups and contexts.
The results present a notable picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This stark contrast highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology captured actual clinical results rather than experimental conditions, providing practical evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection causes deep inflammation in the lungs and airways, making it perilously hard for affected infants to feed and breathe properly. Parents frequently observe their babies visibly struggling, their chests rising whilst they attempt to draw enough air into their compromised lungs. Whilst the majority of babies recover with clinical support, a small but significant number die from RSV complications annually, making prevention through vaccination a critical public health priority for protecting the most vulnerable and youngest individuals in the population.
- RSV triggers inflammation in lungs, resulting in severe breathing difficulties in infants
- Approximately half of newborns acquire the infection during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies need serious hospital treatment for RSV each year
- Small numbers of babies succumb to RSV related complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have emphasised the significance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.
The messaging from health authorities remains clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Some areas have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These regional differences reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts launching varied communication campaigns to reach women during pregnancy
- Regional disparities in immunisation take-up in different parts of England require targeted improvement
- Community health services adapting programmes to suit local requirements and situations
Practical implications and parental perspectives
The vaccine’s remarkable effectiveness translates into concrete gains for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% reduction in admissions means thousands of infants spared from critical disease. Parents no longer face the distressing scenario of seeing their babies gasping for air or struggle to eat, symptoms that mark severe RSV infections. The vaccine has markedly changed the picture of neonatal breathing health, providing expectant mothers a proactive tool to protect their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab highlights the life-altering consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to pregnant women navigating their final trimester, changing what was once an predictable seasonal threat into a manageable health risk.